[1] Thandra K C, Barsouk A, Saginala K, et al. Epidemiology of lung cancer[J]. Contemp Oncol(Pozn), 2021,25(1):45-52.
[2] Zheng R S, Chen R, Han B F, et al.[Cancer incidence and mortality in China, 2022][J]. Zhonghua Zhong Liu Za Zhi, 2024,46(3):221-231.
[3] Kumar N R, Premalatha K, Suvitha S. Lung disease detection using Self-Attention Generative Adversarial Capsule network optimized with sun flower Optimization Algorithm[J]. Biomedical Signal Processing and Control, 2023,79(1746-8094):104241.
[4] Li W, Feng S, Wu H, et al. Comprehensive analysis of CDK1-associated ceRNA network revealing the key pathways LINC00460/LINC00525-Hsa-Mir-338-FAM11 1/ZWINT as prognostic biomarkers in lung adenocarcinoma combined with experiments[J]. Cells, 2022,11(2073-4409):1220.
[5] Jakopovic M, Brcic L, Miic M, et al. Rates of EGFR, KRAS and ALK gene changes in lung cancer patients in Croatia[J]. J Clin Oncol, 2016,34(0732-183X):e23238.
[6] Wang S, Young M J, Wang Y C, et al. USP24 promotes drug resistance during cancer therapy[J]. Cell Death & Differentiation, 2021,28(1350-9047):2690-2707.
[7] Gao W, Wen C P, Wu A, et al. Association of computed tomographic screening promotion with lung cancer overdiagnosis among asian women[J]. JAMA Intern Med, 2022,182(3):283-290.
[8] Duan J, Zhong B, Fan Z, et al. DNA methylation in pulmonary fibrosis and lung cancer[J]. Expert Rev Respir Med, 2022,16(5):519-528.
[9] Liu T, Guo W, Luo K, et al. Smoke-induced SAV1 Gene Promoter hypermethylation disrupts YAP negative feedback and promotes malignant progression of non-small cell lung cancer[J]. Int J Biol Sci, 2022,18(11):4497-4512.
[10] Zhang Z, Li J, Liu H, et al. Impact of systemic immune-inflammation index in patients with limited-stage small cell lung cancer[J]. J Clin Oncol, 2023,41(0732-183X):e20626.
[11] 李 忠. 李忠肿瘤验案精选[M].北京:人民军医出版社, 2011:10-18.
[12] 张 怡, 王笑民. 肺癌病机证候研究概况[J]. 中华中医药杂志, 2013,28(11):3325-3328.
[13] Zhang X, Qiu H, Li C, et al. The positive role of traditional Chinese medicine as an adjunctive therapy for cancer[J]. Biosci Trends, 2021,15(5):283-298.
[14] Maiga A W, Deppen S A, Denton J, et al. Uptake of video-assisted thoracoscopic lung resections within the veterans affairs for known or suspected lung cancer[J]. JAMA Surg, 2019,154(6):524-529.
[15] Zhang F, Xu L, Lu H, et al. Short-term surgical outcomes for lobectomy between robot-assisted thoracic surgery and uniportal video-assisted thoracoscopic surgery[J]. Front Oncol, 2022,12:914059.
[16] Bertolaccini L, Casiraghi M, Uslenghi C, et al. Advances in lung cancer surgery: the role of segmentectomy in early-stage management[J]. Expert Review of Respiratory Med, 2024,10(1747-6348):1-7.
[17] Cai H, Wang Y, Qin D, et al. Advanced surgical technologies for lung cancer treatment: Current status and perspectives[J]. Engineered Regeneration, 2023,4(2666-1381):55-67.
[18] 娄晨曦, 罗怡晨, 李柏钧, 等. 云南白药对单孔胸腔镜手术中老年肺癌患者的疗效研究[J]. 中国现代医生, 2024,62(24):86-89.
[19] 张时文, 王 欣, 黄 琳, 等. 升陷汤合四物汤加减治疗肺恶性肿瘤疲劳的效果[J]. 中国老年学杂志, 2023,43(6):1308-1312.
[20] 许越淇, 陈妮丹, 肖 航, 等. 刘良徛运用“畅气舒郁通络法”治疗肺癌术后慢性疼痛经验[J]. 中医药通报, 2023,22(11):6-8.
[21] 徐 俊, 孙 平. 六君子汤对非小细胞肺癌术后咳嗽患者的影响[J]. 浙江中医杂志, 2022,57(12):882-883.
[22] Zhao X, Dai X, Wang S, et al. Traditional Chinese medicine integrated with chemotherapy for stage Ⅱ-ⅢA Patients with non-small-cell lung cancer after radical surgery: a retrospective clinical analysis with small sample size[J]. Evidence-based Complementary and Alternative Medicine, 2018,2018(1741-427X):1-7.
[23] Navarro-Martin A, Galiana I L, Berenguer F M, et al. Preliminary study of the effect of stereotactic body radiotherapy(SBRT) on the immune system in lung cancer patients unfit for surgery: immunophenotyping analysis[J]. Int J Mol Sci, 2018,19(12).
[24] Timmerman R D, Paulus R, Pass H I, et al. Stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NRG oncology RTOG 0618 Trial[J]. JAMA Oncol, 2018,4(9):1263-1266.
[25] 孙君阳, 何东初. 健脾补肾方对肿瘤患者放疗后造血及免疫系统的影响[J]. 中国实验方剂学杂志, 2024,30(21):219-226.
[26] 王 敏, 徐鹏飞, 魏鹏飞, 等. 培元抗癌汤联合同步化放疗治疗局部晚期非小细胞肺癌患者的临床观察[J]. 世界中西医结合杂志, 2023,18(7):1417-1422.
[27] 崔王波, 吴 伟, 余 利, 等. 健脾化痰方在肺癌患者化疗期间改善胃肠道不良反应及营养状况的临床研究[J]. 河北中医, 2024,46(7):1074-1077.
[28] 方庆亮, 朱 明, 王 蕾, 等. 养阴清肺汤治疗肺癌放疗并发放射性肺损伤患者的疗效及对其转化生长因子-β1和白细胞介素-6水平的影响[J]. 世界中西医结合杂志, 2024,19(9):1796-1800.
[29] 汪 琼, 袁亚芬, 沈红芳. 耳穴手法按压对肺癌术后化疗患者肺功能、癌因性疲乏的改善研究[J]. 浙江创伤外科, 2024,29(2):350-353.
[30] Zhu X. Clinical effect of auricular point sticking in patients with lung cancer receiving chemotherapy[J]. Proceedings of Anticancer Research, 2021,5(2208-3545):73-77.
[31] Abuarab S F, Talib W H. Immunomodulatory and anticancer activities of barley bran grown in jordan: an in vitro and in vivo study[J]. Frontiers in Nutrition, 2022,9(2296-861X):0-0.
[32] Aikins M E, Xu C, Moon J J. Engineered nanoparticles for cancer vaccination and immunotherapy[J]. Acc Chem Res, 2020,53(10):2094-2105.
[33] Fenis A, Demaria O, Gauthier L, et al. New immune cell engagers for cancer immunotherapy[J]. Nature Reviews Immunology, 2024,0(1474-1733):0-0.
[34] Wang X, Barrera C, Bera K, et al. Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes(TILs) predict clinical benefit for immune checkpoint inhibitors[J]. Science Advances, 2022,8(2375-2548):0-0.
[35] Wang Y, Zhang H. FAT10 is a prognostic biomarker and correlated with immune infiltrates in skin cutaneous melanoma[J]. Front Mol Biosci, 2022,9:805887.
[36] Wang F, Xia T, Liu Z, et al. Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer[J]. Frontiers in Oncology, 2023,13(2234-943X):100.
[37] 杨 鹭, 王中奇. 王中奇运用消风四物汤加减治疗肺癌免疫药物相关性皮疹经验[J]. 中医文献杂志, 2023,41(2):76-78.
[38] 罗家江. 温阳散结汤联合免疫治疗对表皮生长因子受体突变的晚期非小细胞肺癌患者的临床预后的作用分析[J]. 中华中医药学刊,2024,1:1-6.
[39] 王宏君, 陈玺龙, 孙亚男, 等. 艾灸联合加味升阳益胃汤治疗肺鳞癌化疗后骨髓抑制及对免疫功能的影响[J]. 辽宁中医杂志, 2023,50(9):200-204.
[40] 王 涵, 彭 瑾, 金慧茹, 等. 肺癌患者免疫治疗所致肝损伤的影响因素[J]. 肝脏, 2023,28(6):688-693.
[41] 叶知锋, 黄 挺, 胡科科, 等. 艾灸联合免疫检查点抑制剂与化疗治疗晚期非鳞非小细胞肺癌临床研究[J]. 新中医, 2024,56(16):129-135.
[42] Wei Z, Chen J, Zuo F, et al. Traditional Chinese Medicine has great potential as candidate drugs for lung cancer: a review[J]. J Ethnopharmacol, 2023,300:115748.
[43] Li C, Niu M, Wang R, et al. The modulatory properties of Si Jun Zi Tang enhancing anticancer of gefitinib by an integrating approach[J]. Biomed Pharmacother, 2019,111:1132-1140.
[44] Zhang Y, Yao Y, Fu Y, et al. Inhibition effect of oxyepiberberine isolated from coptis chinensis franch. on non-small cell lung cancer based on a network pharmacology approach and experimental validation[J]. Journal of Ethnopharmacology, 2021,278:114267.